Combined oral contraception and obesity are strong predictors of low-grade inflammation in healthy individuals: Results from the Danish Blood Donor Study (DBDS)

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Sørensen, Cecilie J ^a   Pedersen, Ole B ^b   Petersen, Mikkel S ^a   Sørensen, Erik ^c   Kotzé, Sebastian ^a   Thørner, Lise W ^c   Hjalgrim, Henrik ^d   Rigas, Andreas S ^c   Møller, Bjarne ^a   Rostgaard, Klaus ^d   Riiskjær, Mads ^a   Ullum, Henrik ^c   Erikstrup, Christian ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NAESTVED HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BODY MASS; DENMARK; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; LOW GRADE INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL CONTRACEPTION; PREMENOPAUSE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; WAIST CIRCUMFERENCE; BLOOD DONOR; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPLICATION; HEALTH; MENOPAUSE; METABOLISM; MULTIVARIATE ANALYSIS; SMOKING; STATISTICAL MODEL;

ADULT; BLOOD DONORS; C-REACTIVE PROTEIN; COHORT STUDIES; CONTRACEPTIVES, ORAL, COMBINED; DENMARK; FEMALE; HEALTH; HUMANS; INFLAMMATION; LOGISTIC MODELS; MALE; MENOPAUSE; MULTIVARIATE ANALYSIS; OBESITY; SMOKING;

EID: 84895550485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088196     Document Type: Article

References (48)

1. Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111: 1805-1812. doi:10.1172/JCI18921. (Pubitemid 38057722)
2. Du Clos TW (2000) Function of C-reactive protein. Ann Med 32: 274-278.
3. Rhodes B, Fürnrohr BG, Vyse TJ (2011) C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol 7: 282-289. doi:10.1038/nrrheum.2011.37.
4. Grad E, Danenberg HD (2013) C-reactive protein and atherothrombosis: Cause or effect? Blood Rev 27: 23-29. doi:10.1016/j.blre.2012.12.001.
5. Chenillot O, Henny J, Steinmetz J, Herbeth B, Wagner C, et al. (2000) High Sensitivity C-Reactive Protein: Biological Variations and Reference Limits. Clin Chem Lab Med 38: 1003-1011. doi:10.1515/CCLM.2000.149.
6. Kluft C, de Maat MPM (2002) Sensitive markers of inflammation make it possible to study the chronic process: the rise of interest in low levels of Creactive protein. Vascul Pharmacol 39: 99-104. (Pubitemid 36398230)
7. Rifai N, Ridker PM (2003) Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin Chem 49: 666-669. (Pubitemid 36379538)
8. Imhof A, Fröhlich M, Loewel H, Helbecque N, Woodward M, et al. (2003)Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 49: 669-672. (Pubitemid 36379539)
9. Villegas R, Xiang YB, Cai H, Elasy T, Cai Q, et al. (2010) Lifestyle determinants of c-reactive protein in middle-aged, urban Chinese men. Nutr Metab Cardiovasc Dis NMCD. Available: http://www.ncbi.nlm.nih.gov/pubmed/21111583. Accessed 4 July 2011.
10. Dreon DM, Slavin JL, Phinney SD (2003) Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci 73: 1245-1252. doi:10.1016/S0024-3205(03)00425-9. (Pubitemid 36794589)
11. Soska V, Fiala J, Nebeska K, Jarkovsky J, Hruba D (2011) The atherogenic index of plasma is increased by hormonal contraception. Scand J Clin Lab Invest: 1-7. doi:10.3109/00365513.2011.553240.
12. Allin KH, Nordestgaard BG (2011) Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48: 155-170. doi:10.3109/10408363.2011.599831.
13. Hage FG, Szalai AJ (2007) C-Reactive Protein Gene Polymorphisms, C-Reactive Protein Blood Levels, and Cardiovascular Disease Risk. J Am Coll Cardiol 50: 1115-1122. doi:10.1016/j.jacc.2007.06.012. (Pubitemid 47375011)
14. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, et al. (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375: 132-140. doi:10.1016/S0140-6736(09)61717-7.
15. Nielen MMJ, Van Schaardenburg D, Reesink HW, Twisk JWR, Van De Stadt RJ, et al. (2004) Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 50: 2423-2427. doi:10.1002/art.20431. (Pubitemid 39062700)
16. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, et al. (2003) C-reactive protein and the risk of developing hypertension. JAMA J Am Med Assoc 290: 2945-2951. doi:10.1001/jama.290.22.2945. (Pubitemid 37505526)
17. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, et al. (2008) C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer J Int Cancer 123: 1133-1140. doi:10.1002/ijc.23606.
18. C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction (2012). N Engl J Med 367: 1310-1320. doi:10.1056/NEJMoa1107477.
19. Edgren G, Tran TN, Hjalgrim H, Rostgaard K, Shanwell A, et al. (2007) Improving health profile of blood donors as a consequence of transfusion safety efforts. Transfusion (Paris) 47: 2017-2024. doi:10.1111/j.1537-2995.2007.01425. x. (Pubitemid 47623971)
20. Atsma F, Veldhuizen I, de Vegt F, Doggen C, de Kort W (2011) Cardiovascular and demographic characteristics in whole blood and plasma donors: results from the Donor InSight study. Transfusion (Paris) 51: 412-420. doi:10.1111/j.1537-2995.2010.02867.x.
21. Pedersen OB, Erikstrup C, Kotzé SR, Sørensen E, Petersen MS, et al. (2012) The Danish Blood Donor Study: a large, prospective cohort and biobank for medical research. Vox Sang 102: 271-271. doi:10.1111/j.1423-0410. 2011.01553.x.
22. Lægehåndbogen: Klimakteriet. Available: https://www.sundhed. dk/sundhedsfaglig/laegehaandbogen/gynaekologi/tilstande-og-sygdomme/diverse/ klimakteriet/. Accessed Martz 2011 (n.d.).
23. NHLBI Obesity Education Initiative Expert Panel on the Identification E (1998) Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Available: http://www.ncbi.nlm.nih.gov/books/ NBK2003/. Accessed 24 June 2013.
24. Cnattingius S, Villamor E, Johansson S, et al (2013) MAternal obesity and risk of preterm delivery. JAMA 309: 2362-2370. doi:10.1001/jama.2013.6295.
25. Waist Circumference and Waist-Hip Ratio. Report of a WHO Expert Consultation, Geneva, 8-11 December 2008. Available: http://www.who.int/ nutrition/publications/obesity/WHO-report-waistcircumference-and-waisthip-ratio/ en/. Accessed 2011. (n.d.).
26. Afzal S, Bojesen SE, Nordestgaard BG (2013) Low Plasma 25-Hydroxyvitamin D and Risk of Tobacco-Related Cancer. Clin Chem 59: 771-780. doi:10.1373/clinchem.2012.201939.
27. MIT LIV - MIN SUNDHED 2007-2009. Available://www.laengelevekbh.kk. dk/Sundhed/~/media/folkesundhed/Files/Arbejdspladser/ Vaerktoejssamlingmitlivminsundhed.ashx. Accessed November 2009. (n.d.).
28. Fødevarestyrelsen (n.d.) Tips om fisk. Ministeriet for familie- og forbrugeranliggender. Fødevarestyrelsen. Available http://www. foedevarestyrelsen.dk/Publikationer/Alle%20publikationer/2005208.pdf. Accessed February 2005.
29. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, et al. (2000) AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Stroke J Cereb Circ 31: 2751-2766.
30. Lee J, Nordestgaard BG, Dahl M (2009) Elevated ACE activity is not associated with asthma, COPD, and COPD co-morbidity. Respir Med 103: 1286-1292. doi:10.1016/j.rmed.2009.04.003.
31. Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GDO, et al. (2000)Immunoradiometric Assay of Circulating C-Reactive Protein: Age-related Values in the Adult General Population. Clin Chem 46: 934-938. (Pubitemid 30461263)
32. Van Rooijen M, Hansson LO, Frostegård J, Silveira A, Hamsten A, et al. (2006)Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 4: 77-82. doi:10.1111/j.1538-7836.2005.01690.x.
33. Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103: 1813-1818.
34. Morin-Papunen L, Martikainen H, McCarthy MI, Franks S, Sovio U, et al. (2008) Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population. Am J Obstet Gynecol 199: 529.e1-529.e10. doi:10.1016/j.ajog.2008. 04.013.
35. Saadeddin SM, Habbab MA, Ferns GA (2002) Markers of inflammation and coronary artery disease. Med Sci Monit Int Med J Exp Clin Res 8: RA5-12.
36. Ledue TB, Rifai N (2001) High sensitivity immunoassays for C-reactive protein: promises and pitfalls. Clin Chem Lab Med CCLM FESCC 39: 1171-1176. doi:10.1515/CCLM.2001.185. (Pubitemid 33133638)
37. Buchbinder S, Kratzsch J, Fiedler GM, Yar V, Brügel M, et al. (2008) Body weight and oral contraceptives are the most important modulators of serum CRP levels. Scand J Clin Lab Invest 68: 140-144. doi:10.1080/00365510701487727. (Pubitemid 351481731)
38. Raitakari M, Mansikkaniemi K, Marniemi J, Viikari JSA, Raitakari OT (2005) Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: The Cardiovascular Risk in Young Finns Study. J Intern Med 258: 428-434. doi:10.1111/j.1365-2796.2005.01563.x. (Pubitemid 41546558)
39. Hung J, Knuiman MW, Divitini ML, Davis T, Beilby JP (2008) Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. Am J Cardiol 101: 193-198. doi:10.1016/j.amjcard.2007.07.061.
40. Skouby SO (2010) Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 15: S42-S53. doi:10.3109/13625187.2010.533002.
41. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (2011) Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 343: d6423.
42. Shulman LP (2011) The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives. Am J Obstet Gynecol 205: S9-S13. doi:10.1016/j.ajog.2011.06.057.
43. Wilson NM, Laursen M, Lidegaard Ø (2012) Oral contraception in Denmark 1998-2010. Acta Obstet Gynecol Scand 91: 810-815. doi:10.1111/j.1600- 0412.2012.01416.x.
44. Salobir B, Sabovic M (2006) A metabolic syndrome independent association between overweight, fibrinolysis impairment and low-grade inflammation in young women with venous thromboembolism. Blood Coagul Fibrinolysis Oct 2006 17: 551-556. doi:10.1097/01.mbc.0000245298.64644.0a. (Pubitemid 44434966)
45. Dawood MY (2006) Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 108: 428-441. doi:10.1097/01.AOG.0000230214.26638.0c.
46. Janssen EB, Rijkers ACM, Hoppenbrouwers K, Meuleman C, D'Hooghe TM (2013) Prevalence of endometriosis diagnosed by laparoscopy in adolescents with dysmenorrhea or chronic pelvic pain: a systematic review. Hum Reprod Update 19: 570-582. doi:10.1093/humupd/dmt016.
47. Koninckx PR, Kennedy SH, Barlow DH (1998) Endometriotic disease: the role of peritoneal fluid. Hum Reprod Update 4: 741-751. doi:10.1093/humupd/4.5.741. (Pubitemid 29041489)
48. Koch MB, Davidsen M, Juel K (n.d.) Social ulighed i sundhed, sygelighed og trivsel 2010 og udviklingen siden 1987. Statens Institut for Folkesundhed, Syddansk Universitet, København 2012. Available: http://www. sifolkesundhed.dk/upload/social-ulighed-164-sider-maj-2012.pdf. Accessed May 2012.